Gujarat Themis Biosyn Ltd (GUJTHEM)
₹360.50
Mkt cap
₹3,928 Cr
P/E ratio
84.20
P/B
13.66
Div yield
0.19%
ROE
17.40%
ROCE
17.90%
EPS (TTM)
₹4.28
Book value
₹26
52W range
227–470
Sector
Healthcare
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process [1]
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−23.28% from high₹361
₹227+58.88% from low₹470
Current
₹360.50
Prev close
₹360.95
Day
−0.12%
Price performance
1D
−0.12%
1W
−0.95%
1M
−8.39%
3M
+0.16%
6M
+7.92%
1Y
−2.90%
YTD
−17.16%
Financials
FRevenue, profit & margin
P/E ratio
84.2×
GUJTHEM is 147% above the sector median of 34.0×
GUJTHEM84.2×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 50 | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 42 | 43 | 44 | |
| Expenses | 13 | 26 | 23 | 21 | 21 | 20 | 19 | 21 | 22 | 22 | 21 | 22 | 25 | |
| Operating Profit | 14 | 24 | 17 | 18 | 21 | 19 | 15 | 19 | 16 | 14 | 21 | 21 | 19 | |
| OPM % | 52% | 47% | 42% | 46% | 50% | 48% | 44% | 48% | 42% | 39% | 49% | 49% | 44% | |
| Other Income | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 4 | |
| Profit before tax | 16 | 24 | 17 | 18 | 21 | 18 | 14 | 17 | 16 | 12 | 19 | 17 | 14 | |
| Tax % | 25% | 26% | 26% | 26% | 24% | 26% | 26% | 25% | 25% | 25% | 24% | 26% | 24% | |
| Net Profit | 12 | 18 | 13 | 13 | 16 | 13 | 11 | 13 | 12 | 9 | 14 | 12 | 11 | |
| EPS in Rs | 1.07 | 1.63 | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.10 | 0.83 | 1.31 | 1.14 | 1.00 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202670.87%Promoter
Promoters70.87%0.01
FIIs1.76%0.04
DIIs1.17%
Public26.18%0.03
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Guj. Themis Bio. | ₹360.50 | 84.15 | 3,928 | 0.19% | 11 | −9.25% | 44 | +17.20% | 17.86% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2011bse
Concall transcripts29
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 13h - Please refer to our copies of Newspaper Publication dated 24.07.2026 for Postal Ballot.Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 1d - Postal ballot seeks approval for ₹1,000 crore QIP and ₹1,500 crore debt issuance; voting ends 22 August 2026.Revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011. 21 JulRevised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 21 JulRevised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 21 Jul